Patent ID: 11970549
Assignee: NATIONAL UNIVERISTY CORPORATION UNIVERSITY OF TOYAMA
Field: Biotechnology (Chemistry)
Classification: CPC C  Y | IPC C

Claim 2:
3. The antibody or a fragment thereof according to claim 1, wherein the antibody is any of the following:
(i) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12;
heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29;
light chain CDR2 comprising the amino acid sequence of YTN; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 42,
(ii) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 13;
heavy chain CDR3 comprising an amino acid sequence of any of SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 96, and SEQ ID NO: 97;
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30;
light chain CDR2 comprising the amino acid sequence of YTD; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 43,
(iii) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 14;
heavy chain CDR3 comprising an amino acid sequence of any of SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 96, and SEQ ID NO: 97;
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31;
light chain CDR2 comprising the amino acid sequence of YAD; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 43,
(iv) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
heavy chain CDR3 comprising an amino acid sequence of any of SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 96, and SEQ ID NO: 97;
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31;
light chain CDR2 comprising the amino acid sequence of YAN; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 44,
(v) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 13;
heavy chain CDR3 comprising an amino acid sequence of any of SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 96, and SEQ ID NO: 97;
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31;
light chain CDR2 comprising the amino acid sequence of YAN; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 43,
(vi) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 8;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 16;
heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26;
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 32;
light chain CDR2 comprising the amino acid sequence of DAS; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 45,
(vii) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 9;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 17;
heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 24 or 25,
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 33;
light chain CDR2 comprising the amino acid sequence of GVK; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 46,
(viii) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 18;
heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 27,
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 33;
light chain CDR2 comprising the amino acid sequence of RAK; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 47,
(ix) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 19;
heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 25 or 24,
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34;
light chain CDR2 comprising the amino acid sequence of GAK; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 46, and
(x) an antibody comprising
heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 11;
heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20;
heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 28,
light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 35;
light chain CDR2 comprising the amino acid sequence of TAS; and
light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 48.